Diffuse mesothelioma of the peritoneum: A pathological study of 64 tumours treated with cytoreductive therapy

Pathology

Volumn 45, Issue 5, 2013, Pages 464-473

  Lee, Michael ^a   Alexander, H Richard ^a   Burke, Allen ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Adenomatoid tumour; Deciduoid; Lymphohistiocytoid; Mesothelioma; Multicystic; Peritoneum

Indexed keywords

PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL PROLIFERATION; DRUG THERAPY; FEMALE; HUMAN; HYPERTHERMIC THERAPY; LUNG TUMOR; MALE; MESOTHELIOMA; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEUM; PERITONEUM TUMOR; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DRUG THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; PAIRED BOX TRANSCRIPTION FACTORS; PERITONEAL NEOPLASMS; PERITONEUM; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84887882312     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283631cce     Document Type: Article

References (33)

1. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004; 159: 107-12.
2. Ordonez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol 2006; 13: 16-25.
3. Barnetson RJ, Burnett RA, Downie I, Harper CM, Roberts F. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006; 125: 67-76.
4. Gao FF, Krasinskas AM, Chivukula M. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of mullerian origin? Appl Immunohistochem Mol Morphol 2012; 20: 272-6.
5. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008; 32: 1566-71.
6. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21: 4560-7.
7. Baratti D, Vaira M, Kusamura S, et al. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 2010; 36: 1047-53.
8. Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH. Multiinstitutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg 2011; 98: 60-4.
9. Clarke JM, Helft P. Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: a case report and review of the literature. J Med Case Rep 2010; 4: 346.
10. Hoekstra AV, Riben MW, Frumovitz M, et al. Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. Gynecol Oncol 2005; 98: 161-7.
11. Machlenkin S, Diment J, Kashtan H. Benign cystic mesothelioma of the peritoneum. Isr Med Assoc J 2006; 8: 511-2.
12. Weiss SW, Tavassoli FA. Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol 1988; 12: 737-46.
13. Galateau-Salle F, Attanoos R, Gibbs AR, et al. Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases. Am J Surg Pathol 2007; 31: 711-6.
14. Elias D, Souadka A, Fayard F, et al. Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery). Eur J Surg Oncol 2012; 38: 503-8.
15. Malpica A, Sant'Ambrogio S, Deavers MT, Silva EG. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases. Am J Surg Pathol 2012; 36: 117-27.
16. Baratti D, Kusamura S, Nonaka D, et al. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol 2007; 14: 2790-7.
17. Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer 2005; 104: 2181-8.
18. Johansson L, Linden CJ. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest 1996; 109: 109-14.
19. Geyer SJ. Malignant biphasic peritoneal mesothelioma in a child: Consideration of other diagnostic possibilities. Diagn Cytopathol 2013; 41: 658.
20. Hirano H, Fujisawa T, Maekawa K, et al. Malignant mesothelioma of the peritoneum: case reports and immunohistochemical findings including Ki-67 expression. Med Mol Morphol 2010; 43: 53-9.
21. Lainakis G, Zagouri F, Kastritis E, et al. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Tumori 2011; 97: 25-9.
22. Alexander HR Jr. Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. Ann Surg Oncol 2010; 17: 21-2.
23. Hove Kanstrup M, Joergensen A, Grove A. Benign multicystic peritoneal mesothelioma. Acta Obstet Gynecol Scand 2002; 81: 1083-5.
24. Dellaportas D, Kairi-Vassilatou E, Lykoudis P, et al. Peritoneal mesotheliomas mimicking adnexal tumors. Clinicopathological characteristics of four cases and a short literature review. Euro J Gynaecol Oncol 2012; 33: 101-4.
25. Baratti D, Kusamura S, Cabras AD, et al. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2010; 17: 45-53.
26. Shia J, Erlandson RA, Klimstra DS. Deciduoid mesothelioma: a report of 5 cases and literature review. Ultrastruct Pathol 2002; 26: 355-63.
27. Monaghan H, Al-Nafussi A. Deciduoid pleural mesothelioma. Histopathology 2001; 39: 104-6.
28. Ordonez NG. Deciduoid mesothelioma: report of 21 cases with review of the literature. Mod Pathol 2012; 25: 1481-95.
29. Rekhi B, Pathuthara S, Ajit D, Kane SV. Signet-ring cells-a caveat in the diagnosis of a diffuse peritoneal mesothelioma occurring in a lady presenting with recurrent ascites: an unusual case report. Diagn Cytopathol 2010; 38: 435-9.
30. Maeda S, Hosone M, Katayama H, et al. Deciduoid mesothelioma in the pelvic cavity. Pathol Int 2004; 54: 67-72.
31. Ascoli V, Facciolo F, Rahimi S, et al. Concomitant malignant mesothelioma of the pleura, peritoneum, and tunica vaginalis testis. Diagn Cytopathol 1996; 14: 243-8.
32. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 2010; 34: 627-35.
33. Takeshima Y, Amatya VJ, Kushitani K, Inai K. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol 2008; 130: 771-9.